Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03846310
What this trial is testing

Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of Lung+1 more
Arcus Biosciences, Inc. 77
Large-scale testing (Phase 3)Study completedNCT02586025
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Who this might be right for
Breast Cancer
Hoffmann-La Roche 329
Testing effectiveness (Phase 2)Looking for participantsNCT05987826
What this trial is testing

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Shanghai Zhongshan Hospital 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04695925
What this trial is testing

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Who this might be right for
Non-small Cell CarcinomaEGFR Gene Mutation
Li Zhang, MD 294
Not applicableNot Yet RecruitingNCT06117644
What this trial is testing

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIA+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 30
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Testing effectiveness (Phase 2)Looking for participantsNCT04322890
What this trial is testing

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationALK Gene Mutation+2 more
Hunan Province Tumor Hospital 6,000
Not applicableEnded earlyNCT00828620
What this trial is testing

Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project

Who this might be right for
Metastatic Colorectal Cancer
Universitaire Ziekenhuizen KU Leuven 21
Testing effectiveness (Phase 2)UnknownNCT04646824
What this trial is testing

Almonertinib With Chemotherapy in mEGFR NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Tianjin Medical University Cancer Institute and Hospital 10
Large-scale testing (Phase 3)Study completedNCT01940497
What this trial is testing

The Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 240
Large-scale testing (Phase 3)Ended earlyNCT01244191
What this trial is testing

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Who this might be right for
Non Squamous, Non-small-cell Lung Cancer
Daiichi Sankyo 1,048
Not applicableStudy completedNCT02991274
What this trial is testing

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Who this might be right for
Locally Advanced or Metastatic EGFR(+) NSCLC Patients
AstraZeneca 897
Testing effectiveness (Phase 2)Study completedNCT00910676
What this trial is testing

Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors

Who this might be right for
Metastatic Colorectal CancerNon-Small-Cell Lung Carcinoma
Centre Oscar Lambret 30
Early research (Phase 1)Study completedNCT01859026
What this trial is testing

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Who this might be right for
Lung CancerNon-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Large-scale testing (Phase 3)Looking for participantsNCT06417008
What this trial is testing

HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company 1,080
Early research (Phase 1)Not Yet RecruitingNCT05940116
What this trial is testing

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerSolid Tumor
Hansoh BioMedical R&D Company 322
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Post-approval studies (Phase 4)Not Yet RecruitingNCT07469488
What this trial is testing

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)VTE (Venous Thromboembolism)Rash Due to Epidermal Growth Factor Receptor Inhibitors+1 more
Shanghai Pulmonary Hospital, Shanghai, China 122
Testing effectiveness (Phase 2)Study completedNCT03727724
What this trial is testing

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 37
Not applicableStudy completedNCT02475720
What this trial is testing

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 2,000
Next Page